Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
INCYthis companyIncyte Corporation	$120.91	14.99×	3.73×	3.75×	9.23×	-2.4%	92.8%	26.1%	25.0%	24.9%	20.6%	7.0%	0.01×	-1.72×	553.04×	3.32×	0.0%	6	10.87	3	B+
AVBPArriVent BioPharma, Inc.	$14.54	-4.66×	2.52×	0×	-4.38×	-92.2%	0.0%	0.0%	0.0%	-54.1%	-57.8%	-20.8%	0×	0.27×	0×	12.83×	0.0%	2	12.15	2	C+
CGEMCullinan Therapeutics, Inc.	$11.61	-2.78×	1.5×	0×	-2.39×	-90.4%	0.0%	0.0%	0.0%	-53.8%	-58.7%	-28.8%	0.01×	0.39×	0×	10.25×	0.0%	1	9.54	2	C
EXELExelixis, Inc.	$71.55	15.13×	5.48×	5.1×	12.5×	124.2%	96.4%	37.6%	33.7%	36.2%	29.7%	7.1%	0.08×	-0.34×	0×	3.56×	0.0%	6	18.06	4	A
LEGNLegend Biotech Corporation	$24.25	-13.59×	4×	3.89×	-15.15×	-9886.0%	60.3%	-13.3%	-28.8%	-29.6%	-9.6%	-4.2%	0.41×	2.1×	-6.38×	1.96×	0.0%	3	4.12	1	C-
LGNDLigand Pharmaceuticals Incorporated	$310.70	29.36×	3.59×	13.64×	20.41×	-87.1%	97.5%	17.6%	46.4%	12.2%	2.4%	1.3%	0.44×	1.43×	10.01×	22.23×	0.0%	5	3.83	2	C
Peer median	—	-2.78×	3.59×	3.89×	-2.39×	-90.4%	60.3%	0.0%	0.0%	-29.6%	-9.6%	-4.2%	0.08×	0.39×	0×	10.25×	0.0%	3	9.54	2	—